World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
139
Citations
88446
World Ranking
1734
National Ranking
992

Research.com Recognitions

  • Member of the Association of American Physicians
  • Member of the Association of American Physicians

Overview

What is he best known for?

The fields of study he is best known for:

  • Internal medicine
  • Diabetes mellitus
  • Type 2 diabetes

Steven E. Kahn focuses on Internal medicine, Endocrinology, Diabetes mellitus, Insulin and Type 2 diabetes. His research is interdisciplinary, bridging the disciplines of Placebo and Internal medicine. Endocrinology is frequently linked to Pathogenesis in his study.

Steven E. Kahn combines subjects such as Physical therapy and Hazard ratio with his study of Diabetes mellitus. His Insulin research integrates issues from Adipose tissue, Hypothalamus and Metabolism. His research investigates the connection with Type 2 diabetes and areas like Weight loss which intersect with concerns in Overweight and Incidence.

His most cited work include:

  • Mechanisms linking obesity to insulin resistance and type 2 diabetes (3314 citations)
  • Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. (2411 citations)
  • Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. (1600 citations)

What are the main themes of his work throughout his whole career to date?

His main research concerns Internal medicine, Endocrinology, Diabetes mellitus, Type 2 diabetes and Insulin. Internal medicine is represented through his Insulin resistance, Impaired glucose tolerance, Obesity, Glucose tolerance test and Body mass index research. His Insulin resistance research incorporates elements of Waist and Cholesterol.

His Diabetes mellitus study frequently draws connections to other fields, such as Research design. His Type 2 diabetes research includes elements of Clinical trial, Weight loss, Overweight, Randomized controlled trial and Physical therapy. His work deals with themes such as Secretion, Carbohydrate metabolism and Arginine, which intersect with Insulin.

He most often published in these fields:

  • Internal medicine (89.16%)
  • Endocrinology (70.91%)
  • Diabetes mellitus (56.08%)

What were the highlights of his more recent work (between 2018-2021)?

  • Internal medicine (89.16%)
  • Diabetes mellitus (56.08%)
  • Type 2 diabetes (38.40%)

In recent papers he was focusing on the following fields of study:

His primary scientific interests are in Internal medicine, Diabetes mellitus, Type 2 diabetes, Endocrinology and Insulin. His Internal medicine research includes elements of Placebo and Prediabetes. His Diabetes mellitus study which covers Prospective cohort study that intersects with Weight change and Family history.

His Type 2 diabetes research is multidisciplinary, incorporating elements of Metformin, Obesity and Glycemic. The Endocrinology study combines topics in areas such as Genetically modified mouse and Transgene. His Insulin research incorporates elements of Adipose tissue and Immune system.

Between 2018 and 2021, his most popular works were:

  • Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial. (423 citations)
  • Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes: The CAROLINA Randomized Clinical Trial. (173 citations)
  • Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA (86 citations)

In his most recent research, the most cited papers focused on:

  • Internal medicine
  • Diabetes mellitus
  • Gene

Steven E. Kahn spends much of his time researching Internal medicine, Diabetes mellitus, Type 2 diabetes, Insulin and Insulin resistance. His Internal medicine study combines topics in areas such as Endocrinology, Nephropathy and Linagliptin. In most of his Endocrinology studies, his work intersects topics such as Amyloid.

His work on Glycemic is typically connected to Coronavirus as part of general Diabetes mellitus study, connecting several disciplines of science. Steven E. Kahn has included themes like Metformin, Research design and Insulin sensitivity, β cell function in his Type 2 diabetes study. Steven E. Kahn combines subjects such as Adipose tissue and Prediabetes with his study of Insulin resistance.

Best Publications

  • Mechanisms linking obesity to insulin resistance and type 2 diabetes

    Steven E. Kahn;Rebecca L. Hull;Kristina M. Utzschneider

  • Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.

    Kahn Se;Haffner Sm;Heise Ma;Herman Wh

  • The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes.

    S. E. Kahn

  • Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes

    R. R. Wing;P. Bolin;F. L. Brancati;G. A. Bray

  • Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future

    Steven E Kahn;Mark E Cooper;Stefano Del Prato

  • Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex.

    Miriam Cnop;P. J. Havel;K. M. Utzschneider;D. B. Carr

  • Quantification of the relationship between insulin sensitivity and beta-cell function in human subjects. Evidence for a hyperbolic function.

    S E Kahn;R L Prigeon;D K McCulloch;E J Boyko

  • Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial.

    Rena R. Wing;Judy L. Bahnson;George A. Bray;Jeanne M. Clark

  • Complex Distribution, Not Absolute Amount of Adiponectin, Correlates with Thiazolidinedione-mediated Improvement in Insulin Sensitivity

    Utpal B. Pajvani;Meredith Hawkins;Terry P. Combs;Michael W. Rajala

  • Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes

    Seth L Masters;Aisling Dunne;Shoba L Subramanian;Rebecca L Hull

  • Reduction in Weight and Cardiovascular Disease Risk Factors in Individuals With Type 2 Diabetes: One-Year Results of the Look AHEAD Trial

    Mark Espeland;Xavier Pi-Sunyer;George Blackburn;Frederick L. Brancati

  • Intra-Abdominal Fat Is a Major Determinant of the National Cholesterol Education Program Adult Treatment Panel III Criteria for the Metabolic Syndrome

    Darcy B. Carr;Kristina M. Utzschneider;Rebecca L. Hull;Keiichi Kodama

  • Obesity and Type 2 Diabetes: What Can Be Unified and What Needs to Be Individualized?

    Robert H. Eckel;Steven E. Kahn;Ele Ferrannini;Allison B. Goldfine

  • Review: The role of insulin resistance in nonalcoholic fatty liver disease.

    Kristina M. Utzschneider;Steven E. Kahn

  • Glucose Levels and Risk of Dementia

    Paul K. Crane;Rod Walker;Rebecca A. Hubbard;Ge Li

  • Prevention of Diabetes in Women with a History of Gestational Diabetes: Effects of Metformin and Lifestyle Interventions

    Robert E. Ratner;Costas A. Christophi;Boyd E. Metzger;Dana Dabelea

  • Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes.

    Donna H Ryan;Mark A Espeland;Gary D Foster;Steven M Haffner

  • Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial.

    Julio Rosenstock;Vlado Perkovic;Odd Erik Johansen;Mark E. Cooper

  • The Importance of β-Cell Failure in the Development and Progression of Type 2 Diabetes

    Steven E. Kahn

  • Effect of valsartan on the incidence of diabetes and cardiovascular events.

    John McMurray;R Holman;Steven Haffner;M Bethel

Frequent Co-Authors

Edward J. Boyko
Edward J. Boyko University of Washington
Wilfred Y. Fujimoto
Wilfred Y. Fujimoto University of Washington
William C. Knowler
William C. Knowler National Institutes of Health
Paul W. Franks
Paul W. Franks Lund University
Jose C. Florez
Jose C. Florez Harvard University
Edward S. Horton
Edward S. Horton Harvard Medical School
David M. Nathan
David M. Nathan Harvard University
Daniel Porte
Daniel Porte University of California, San Diego
Bernard Zinman
Bernard Zinman University of Toronto
Robert H. Knopp
Robert H. Knopp University of Washington

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re passionate about medicine but seeking alternative or flexible career pathways, numerous online programs now make it easier to enter the healthcare field. Affordable online nursing degrees are a popular option, as they allow students to balance their studies with work or family commitments. For those considering further specialization, Family Nurse Practitioner (FNP) programs can increase responsibility and earning potential. Plenty of students search for the cheapest online fnp program to help reduce overall costs.

There is growing demand for bachelor’s-prepared nurses nationwide, driving interest in the cheapest rn to bsn program options. If affordability is key, you can also explore affordable online nursing programs that help keep expenses manageable while preparing you for patient care roles.

Looking to reach the highest levels of nursing practice or academic research? Many schools now offer online doctoral options, and finding the cheapest dnp programs online is a smart step for those wanting leadership roles or teaching positions. These pathways offer dynamic, accessible ways to pursue a meaningful healthcare career without the cost of traditional, on-campus programs.

Best Scientists Citing Steven E. Kahn

Trending Scientists